



Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Pericles CALIAS et al.

Serial No.: 10/511,373 Filed: October 14, 2004

For: Cross-Linked Hyaluronate Compounds

Examiner: Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 13, 2005 (Date of Deposit)

Name of applican, assigned or Registered Representative

Learning Signature

July 13, 2005

Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b),

1/2

B

or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

> Respectfully submitted. COHEN, PONTANI, LIEBERMAN & PAVANE

Kent H. Cheng Reg. No. 33,849

551 Fifth Avenue, Suite 1210

New York, New York 10176

(212) 687-2770

Dated: July 13, 2005

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Apperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

4 79 Roge Marte for Form 1449/PTO		Complete if Known			
				Application Number	10/511,373
INFORMATION DISCLOSURE	Filing Date	October 14, 2004			
	STATEMENT BY APPLICANT			First Named Inventor	Pericles CALIAS
(Use as many sheets as necessary)	Art Unit				
1	(555 45 1141)	, u	,	Examiner Name	
Sheet	1	of	3	Attorney Docket Number	4830-13PUS

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind-Code 2 (sf			Figures Appear
/J.L./		US-3,338,885	08/29/1967	Coker et al.	
/J.L./		US-3,376,263	04/02/1968	Ishida et al.	
/J.L./		US-3,468,818	09/23/1969	Phillips	
/J.L./		US-3,828,024	08/06/1974	Breslow	
/J.L./		US-5,614,595	03/25/1997	Bender et al.	
/J.L./		US-6,723,709	04/20/2004	Pressato et al.	
		US-			

Cite			Name of Patentee or	Pages, Columns, Lines,	T <sup>6</sup>
NO.	Country Code <sup>3</sup> Number <sup>4</sup> Kind-Code <sup>5</sup> (if known	MM-DD-1111	Applicant of Cited Document	Relevant Figures Appear	
	GB1211553	11/11/1970	Lubowitz et al.		
	DE1270287	09/27/1965	Manecke et al.	Abstract	
	DE1243687	12/28/1967	Bestain et al.	Abstract	
	SU1723125	03/30/1992	Vasileva	Abstract	
	Cite No. 1	No. 1 Country Code <sup>1</sup> Number <sup>4</sup> Kind-Code 3 (ff bares  GB1211553  DE1270287  DE1243687	No. 1 Country Code* Number* MM-DD-YYYY Kind-Code* Vitewes   GB1211553 11/11/1970   DE1270287 09/27/1965   DE1243687 12/28/1967	No.   Country Code* Number*   MM-DD-YYYY   Applicant of Cited Document   Kind-Code * Piumene   Kind-Code * P	No.   Country Code* Number*   MM-DD-YYYY   Applicant of Cited Document   Where Relevant Passages or Relevant Figures Appear

Signature	/Jonathan Lau/	Considered	06/15/2008
*EXAMINER: Initial if refo Include copy of this form w	erence considered, whether or not citation is in conformance ith next communication to applicant. Applicant's unique of	e with MPEP 609. Draw line through citation itation designation number (ontional). See K	if not in conformance and not considered, inds Codes of USPTO Patent Documents at

www.uspto.gov or MPEP 901.04. Etem Office that issued the document, by the two-letter code (WPE) Sandard ST.J. Fee Japanese pears do user to stand on the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Sandard ST.J. Fee Japanese pears do use to precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Sandard ST.J. Fee Japanese pears do to place a check mark their Effigible language Translation is a stached. Standard ST. 16 if possible. 'Applicant is to place a check mark here if Engish language Translation is attached.

This collection of information is required by JCTR IS 17 and 18.9. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conflicientially is governed by 35 U.SC. 122 and JCTR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and switching the complete application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your equiple to complete this form and/or suggestions for reducing this burden, should be seen to the Chif Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, 10TH annual suggestions for requesting this contact, amount to sent to the ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need accelerace in complaine the form cell LARGE-PTO-0100 (LARGE-TRO-0100) and select ontion 2

PTO/SB/08A (04-03)

Approved for use through 0430/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

and the same of th

e for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known					
Application Number	10/511,373				
Filing Date	October 14, 2004				
First Named Inventor	Pericles CALIAS				
Art Unit					
Examiner Name					
Attorney Docket Number	4830-13PUS				

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
/J.L./		W. McCoull et al., "Recent Synthetic Applications of Chiral Aziridines", Synthesis 2000, No. 10, pp. 1347-1365.					
/J.L./		G. Sosnovsky et al., "In the Search for New Anticancer Drugs. VII", J Cancer Res Clin Oncol No 107(3), pp. 217-220 (1984).					
/J.L./		S. Nishimoto et al., "1.1'-(2.6-Naphthalenedicarbonyl) diaziridine as a Useful Agent for Photocrosslinking of Poly(4-Hydroxystyrene) in Film", Journal of Polymer Science: Polymer Letters Edition, Vol. 22, pp. 323-326 (1984)					
/J.L./		W. Tsuji et al., "Properties of Acrylic Acid Grafted Polypropylene Fiber", Bull. Inst. Chem. Res., Vol. 50, No. 2 (1972).					
/J.L./		Ikeda et al., "Improvement of Crease Resistance of Cotton Fabric by the Grafting with Acrylic Acid and Aftertreatment with Tris (1-Aziridinyl) Phosphine Oxide", Sim'l Gakkaishi, No. 30 (5-6), pp. T292-T298 (1974).					
/J.L./		Larsen et al., "Biocompatibility of Hylan Polymers in Various Tissue Compartments", <i>Materials Research Society Symp. Proc.</i> , No. 394, pp. 149-153 (1995).					
/J.L./		T. Pouyani et al., "Functionalized Derivatives of Hyaluronic Acid Oligosaccharides: Drug Carriers and Novel Biomaterials", <i>Bioconjugate</i> <i>Chem.</i> , Vol. 5, pp. 339-347 (1994)					
/J.L./		T. Laurent et al., "Cross-linked Gels of Hyaluronic Acid", Acta Chem Scand., Vol. 18, No. 1, p. 274 (1964)					
/J.L./		N. Yui et al., "Regulated release of drug microspheres from inflammation responsive degradable matrices of crosslinked hyaluronic acid", <i>Journ. of Controlled Release</i> , Vol. 25, pp. 133-143 (1993)					
/J.L./		N. Yui et al., "Inflammation responsive degradation of crosslinked hyaluronic acid gels", <i>Journ. Of Controlled Release</i> , Vol. 22, p.105-116 (1992).					
Examiner Signature		/Jonathan Lau/	Date Considered	06/15/2008	_		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (opinion). \*See Kinds Codes of USPTO Pates Document, by the two better code (WIPO \*OSandard ST3,) \*For Japanee patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Yet for comment by the appropriate symbols as indicated on the document under WIPO Sandard ST. 16 if yourshie. \*Applicant to place a clock number for its ril English Inappage Translation is anneated.

Softening 5.1 to 1 phosone: - represent on species cores mark sites a negrous sungage reasonance on success.

This collection of information required by 3 CTR 1.57 and 1.58. The information is required to obtain or certain a benefit by the public which is so file (and by the USPTO to 1.58 collection) of information required to obtain on the collection is estimated to a the 2 hours to complete, including gathering performance of the collection is estimated to the 2-hours to complete, including gathering performance of the collection form on the USPTO Time will vary depending one of the collection is estimated to the 2-hours to one of the collection form of the USPTO Time will vary depending one of the collection form of the USPTO Time will vary depending one of the collection formation for the CSPTO Time will vary depending one of the CSPTO Time value of the

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 06S1-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

A.M. Patti et al., "Effect of hyaluronic acid on human chondrocyte cell /J.L./ lines from articular cartilage", Tissue & Cell, Vol. 33(3), pp. 294-300 (2001)Gabriel Herrero-Beaumont et al., "Cartilage and bone biological markers ALL / in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee", Clinica Chimica Acta, Vol. 308, pp. 107-115 (2001) P. Andersson et al., "Enantioselective Addition of Organolithium Reagents /J.L./ to Imines Mediated by C2-Symmetric Bis(aziridine) Ligands, Tetrahedron 54, pp 11549-11566 (1998) D. Tanner et al., "Asymmetric Catalysis via Chiral Aziridines", Acta ALLJChemica Scandinavia, Vol. 50, No. 4, pp. 361-368 (1996). Denmark et al., "Preparation of Chiral Bisoxazolines: Observations on the /J.L./ Effect of Substituents", J. Org. Chem., Vol. 60, pp. 4884-4892 (1995) G. Manecke et al., "Amphotere ion exchanger", Die Makromolekulare 7.1.1.7 Chemie, Vol. 175, pp. 1833-1845 (1974) Kadorkina et al., Izv. Akad. Nauk SSSR Ser. Khim. 4, pp. 882-885 (1991) /J.L./ abstract Watanabe et al., "Synthesis of Aziridine Derivatives from Unsaturated /J.L./ Carboxvlic Acid Halides or Chloroformates an Aziridine", Kogyo Kagaku Zasshi, Vol. 72 (6) pp. 1349-1352 (1969) Vercruysse et al., "Hyauronate Derivatives in Drug Delivery", Critical Reviews<sup>TM</sup> in Therapeutic Drug Carrier Systems, No. 15(5), pp. 513-555 /J.L./ (1998). /J.L./ L. Freed et al., "Biodegradable Polymer Scaffolds for Tissue Engineering", Bio/Technology, Vol. 12, pp. 689-693 (1994). R. Sparer et al., "Controlled Release from Glycosaminoglycan Drug /J.L./ Complexes", Chapter 6, pp. 107-119 (1983) L. Pape et al., "The use of Sodium Hyaluronate (Healon®) in Human /J.L./ Anterior Segment Surgery", Ophthalmology, Vol. 87(7), pp. 698-705 (1980).

Examiner Signature	/Jonathan Lau/	Date Considered	06/15/2008	٦

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPE 609. Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant. \*Applicant's unique citation deep inguinton number (prioring). \*See Kinds Codes of USPTO Patent Documents at wave.unpo.gov or MPEP 901.04. Tiener Office that issued the document, by the two-letter code (WPIO Standard ST.). \*For Applicant patent documents, the indication of the year of the regression of the Emperor man precede the serial number of the patent document. Visid of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 ft Stookhole. \*Applicant to the place a clear cant there if English language Translation is attached.

This collection of information is required by 3T CFR, 193 and 196. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) as application. Confidentiality is governed by 31 USC, 122 and 3T CFR, to file collection contains the object of the collection formation is governed by 31 USC, 122 and 3T CFR, to file collection contains the completed application form to the USPTO. Time will vary depending upon the individual sentential of the mean of time you require to complete this communities for reducing this threat, should be sent to the Cells Information Officer. US Presents and Trademont Officer and Contains the Technology of the Contains of the USPTO Communities and Technology of the Contains of Technology of the Contains of the USPTO Communities and Technology of USPTO Communities and Technology of USPTO Communities and Technology of USPTO Communities the form and USPTO CONTAINS OF USPTO COMMUNITIES OF THE ADDRESS. SEND TO: Communities and Technology of USPTO COMMUNITIES OF THE ADDRESS.